Complete financial analysis of BioSig Technologies, Inc. (BSGM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BioSig Technologies, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Opera Limited (OPRA) Income Statement Analysis – Financial Results
- Frauenthal Holding AG (FKA.VI) Income Statement Analysis – Financial Results
- The Chiba Bank, Ltd. (CHBAF) Income Statement Analysis – Financial Results
- Curbline Properties Corp. (CURB) Income Statement Analysis – Financial Results
- Lithium Chile Inc. (LTMCF) Income Statement Analysis – Financial Results
BioSig Technologies, Inc. (BSGM)
About BioSig Technologies, Inc.
BioSig Technologies, Inc., together with its subsidiaries, operates as medical device company. The company's proprietary product includes precise uninterrupted real-time evaluation of electrograms electrophysiology (PURE EP) system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time. It also focuses on enhancing intracardiac signal acquisition and diagnostic information for the procedures of atrial fibrillation, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures. The company has a research agreement with University of Minnesota to develop novel therapies to treat sympathetic nervous system diseases; and a strategic collaboration with the Mayo Foundation for Medical Education and Research to develop an AI-and machine learning software solution for PURE EP systems. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 18.00K | 286.00K | 441.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 57.00K | 199.00K | 550.00K | 54.35K | 12.40K | 11.70K | 10.48K | 10.48K | 0.00 | 0.00 | 0.00 | 6.80K |
| Gross Profit | 18.00K | 229.00K | 242.00K | -550.00K | -54.35K | -12.40K | -11.70K | -10.48K | -10.48K | 0.00 | 0.00 | 0.00 | -6.80K |
| Gross Profit Ratio | 100.00% | 80.07% | 54.88% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 5.09M | 5.82M | 5.60M | 18.14M | 9.74M | 4.37M | 4.76M | 2.65M | 1.24M | 548.00K | 992.21K | 888.95K | 582.53K |
| General & Administrative | 23.08M | 21.38M | 27.85M | 40.95M | 24.81M | 12.88M | 8.14M | 8.50M | 10.80M | 7.30M | 5.23M | 1.29M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 72.41K | 0.00 |
| SG&A | 23.08M | 21.38M | 27.85M | 40.95M | 24.81M | 12.88M | 8.14M | 8.50M | 10.80M | 7.30M | 5.23M | 1.36M | 484.13K |
| Other Expenses | 361.00K | 293.00K | 198.00K | 94.00K | 54.35K | 12.40K | 11.70K | 10.48K | 10.48K | 15.81K | 17.06K | 0.00 | 0.00 |
| Operating Expenses | 28.53M | 27.49M | 33.65M | 59.18M | 34.60M | 17.26M | 12.91M | 11.16M | 12.04M | 7.87M | 6.24M | 2.26M | 1.07M |
| Cost & Expenses | 28.53M | 27.55M | 33.85M | 59.18M | 34.60M | 17.26M | 12.91M | 11.16M | 12.04M | 7.87M | 6.24M | 2.26M | 1.07M |
| Interest Income | 9.00K | 3.00K | 2.00K | 45.00K | 132.75K | 10.90K | 75.00 | 1.00 | 1.30K | 11.03K | 70.06K | 124.17K | 171.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.90K | 75.00 | 1.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 361.00K | 666.00K | 639.00K | 550.00K | 54.35K | 12.40K | 11.70K | 10.48K | 10.48K | 15.81K | 17.06K | 10.02K | 6.80K |
| EBITDA | -28.15M | -26.97M | -33.21M | -58.63M | -34.42M | -17.25M | -13.11M | -10.73M | -9.45M | -7.85M | -6.22M | -2.25M | -1.14M |
| EBITDA Ratio | -156,394.44% | -9,430.77% | -7,656.69% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -28.51M | -27.27M | -33.41M | -59.18M | -34.60M | -17.26M | -12.91M | -11.16M | -12.04M | -7.87M | -6.24M | -2.26M | -1.07M |
| Operating Income Ratio | -158,400.00% | -9,533.22% | -7,576.19% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -178.00K | 3.00K | 555.00K | 44.00K | 133.20K | 10.90K | 210.54K | -422.91K | 2.58M | -604.80K | -3.57M | -124.17K | -77.76K |
| Income Before Tax | -28.69M | -27.26M | -32.86M | -59.14M | -34.47M | -17.25M | -12.70M | -11.59M | -9.46M | -8.47M | -9.80M | -2.39M | -1.15M |
| Income Before Tax Ratio | -159,388.89% | -9,532.17% | -7,450.34% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 9.00K | -1.49M | -6.97M | -549.05K | 21.79K | -210.54K | 422.91K | -2.58M | 11.03K | 70.06K | 90.86K | 0.00 |
| Net Income | -29.04M | -27.27M | -31.36M | -52.17M | -33.92M | -17.25M | -12.70M | -11.59M | -9.46M | -8.47M | -9.80M | -2.48M | -1.15M |
| Net Income Ratio | -161,338.89% | -9,535.31% | -7,111.56% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -3.95 | -6.33 | -9.36 | -18.70 | -16.39 | -11.89 | -12.42 | -14.86 | -16.77 | -21.95 | -29.94 | -0.76 | -4.43 |
| EPS Diluted | -3.95 | -6.33 | -9.36 | -18.70 | -16.39 | -11.89 | -12.42 | -14.86 | -16.77 | -21.95 | -29.94 | -0.76 | -4.43 |
| Weighted Avg Shares Out | 7.35M | 4.31M | 3.35M | 2.79M | 2.07M | 1.45M | 1.02M | 779.63K | 564.12K | 386.01K | 327.51K | 3.26M | 266.00K |
| Weighted Avg Shares Out (Dil) | 7.35M | 4.31M | 3.35M | 2.79M | 2.07M | 1.45M | 1.02M | 779.63K | 564.12K | 386.01K | 327.51K | 3.26M | 266.00K |
BioSig's Cardiac Signal Processing Technology To Be Featured at Kansas City Heart Rhythm Symposium 2022
Leading Medical Center of Excellence Physician will discuss integrating the PURE EP™ System into their practice and procedural workflow Leading Medical Center of Excellence Physician will discuss integrating the PURE EP™ System into their practice and procedural workflow
BioSig Sees Positive Momentum from Sales Pipeline Growth
Westport, CT, Aug. 16, 2022 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), a medical technology company advancing electrophysiology workflow by delivering greater intracardiac signal fidelity through its proprietary signal processing platform, today announced that it...
BioSig Announces Physician-Initiated Research Protocol at The Kansas City Heart Rhythm Institute
Led by Dhanunjaya DJ Lakkireddy, MD., the study will investigate expanded applications for the signals acquired by BioSig's PURE EP(T.M.) System Led by Dhanunjaya DJ Lakkireddy, MD., the study will investigate expanded applications for the signals acquired by BioSig's PURE...
BioSig Technologies says Kansas City Heart Institute signs purchase agreement for its PURE EP System
BioSig Technologies Inc has announced that Kansas City Heart Institute at Overland Park Regional Medical Center in Kansas City, USA, has signed a purchase agreement to acquire its PURE EP System. Following its evaluation of BioSig's PURE EP System, Overland...
BioSig Announces Purchase Agreement with Kansas City Heart Rhythm Institute at Overland Park Regional Medical Center
Westport, CT, July 07, 2022 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), a medical technology company advancing electrophysiology workflow by delivering greater intracardiac signal fidelity through its proprietary signal processing platform, today announced that Kansas...
BioSig Technologies gets repeat 'Outperform' tag, $4 price target from Noble Capital
BioSig Technologies Inc has earned a reiterated ‘Outperform' rating and $4 price target from analysts at Noble Capital days after pricing a public offering that generated proceeds of $2.9 million. The offering was “[a] bit unexpected, timing-wise, but supports PURE...
BioSig Announces Closing of Public Offering of Common Stock
Westport, CT, June 29, 2022 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) a medical technology company advancing electrophysiology workflow by delivering greater intracardiac signal fidelity through its proprietary signal processing platform, today announced the closing...
BioSig Announces Pricing of Public Offering of Common Stock
Westport, CT, June 24, 2022 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) a medical technology company advancing electrophysiology workflow by delivering greater intracardiac signal fidelity through its proprietary signal processing platform, today announced pricing of...
BioSig Technologies says it intends to offer shares of its common stock in a "best efforts" underwritten public offering
BioSig Technologies, Inc. (NASDAQ:BSGM) has said it intends to offer shares of its common stock in a "best efforts" underwritten public offering. BioSig said it intends to use the net proceeds from the offering for the continuation of commercialization activities...
BioSig Announces Proposed Public Offering of Common Stock
Westport, CT, June 23, 2022 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG...
Source: https://incomestatements.info
Category: Stock Reports